FDA Asks for Input on Post-Market Drug Safety Reporting
Published Date: 5/13/2026
Notice
Summary
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This affects drug makers and healthcare folks who keep track of side effects. They’re asking for comments by July 13, 2026, to help improve the process without adding extra costs or paperwork.
Analyzed Economic Effects
6 provisions identified: 1 benefits, 5 costs, 0 mixed.
Mandatory ICH E2B(R3) Data Standard
If you submit postmarketing individual case safety reports (ICSRs) via FDA's Electronic Submissions Gateway Next Generation (ESG NextGen), those ICSRs must use the ICH E2B(R3) data standards beginning October 1, 2026. FDA began accepting E2B(R3) voluntarily in January 2024 and is now requiring the R3 standard on that date.
10- and 6-Year Recordkeeping Rules
Applicants and manufacturers must keep adverse drug experience records for 10 years under 21 CFR 314.80(j) and 310.305(g). For nonprescription human drug products under section 760(e), responsible persons must retain nonprescription adverse event records for 6 years.
Enhanced Pharmacovigilance Requests by FDA
FDA's January 2024 'Best Practices' may lead to enhanced pharmacovigilance activities for specific products; FDA may request use of targeted data collection tools, expedited submission of adverse experiences beyond minimum reporting, and summarization/assessment at FDA-defined frequencies. FDA has included burden estimates for these enhanced activities in its tables.
Periodic Report Timing Requirement
For approved drug applications, periodic postmarketing safety reports must be submitted quarterly for the first 3 years after U.S. approval and annually thereafter, per 21 CFR 314.80(c)(2) and 600.80(c)(2). These reports must include narratives, summaries, analyses, and indexes of adverse experiences.
5-Day Combination-Product Notification Rule
If a combination product event involves a drug and a constituent applicant receives information about a death, serious injury, or adverse event, that information must be provided to other constituent part applicants no later than 5 calendar days after receipt under 21 CFR 4.103. Rules for submission and recordkeeping for combination products are in 21 CFR 4.104 and 4.105.
Electronic Submission Waivers for Good Cause
All reports and followup reports generally must be submitted electronically, but FDA may grant temporary waivers of the electronic submission requirements for good cause. Waiver requests can be submitted under the cited regulations.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16714, Agency Information Collection Activities; Proposed Collection; Comment Request; Third Party Disclosure and Recordkeeping Requirements for Reportable Food
The Food and Drug Administration (FDA or the Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection provisions of FDA's third-party disclosure and recordkeeping requirements for reportable food.
2026-16712, Agency Information Collection Activities; Proposed Collection; Comment Request; Imports and Electronic Import Entries
The FDA wants your thoughts on how they collect info about imports and electronic import entries. If you’re involved in importing goods, this could affect you! They’re asking for comments by October 16, 2026, to help improve the process without adding extra costs or hassle.
2026-16715, Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational New Drug Application Requirements
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
Previous / Next Documents
Previous: 2026-09542, Agency Information Collection Activity Under OMB Review: Staff Sergeant Parker Gordon Fox Suicide Prevention Grant Program (SSG Fox SPGP)
The VA is renewing its paperwork for the Staff Sergeant Parker Gordon Fox Suicide Prevention Grant Program, which helps communities support veterans at risk of suicide. This means organizations applying for or renewing grants will keep submitting forms to show how they’re helping and following rules. If you’re involved, get ready to send your feedback by June 12, 2026, so the program can keep saving lives smoothly and smartly.
Next: 2026-09544, Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If approved, the renewal keeps these products on the market with their modified risk status, affecting smokers and the tobacco industry starting May 13, 2026.